Investigational Drug Information for AT9283
✉ Email this page to a colleague
What is the development status for investigational drug AT9283?
AT9283 is an investigational drug.
There have been 5 clinical trials for AT9283.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 15th 2010.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Neoplasms. The leading clinical trial sponsors are Astex Pharmaceuticals, Inc., Cancer Research UK, and NCIC Clinical Trials Group.
Summary for AT9283
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 67 |
| WIPO Patent Applications | 25 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 2 (2010-06-15) |
| Vendors | 77 |
Recent Clinical Trials for AT9283
| Title | Sponsor | Phase |
|---|---|---|
| AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia | Cancer Research UK | Phase 1 |
| A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma | Astex Pharmaceuticals, Inc. | Phase 2 |
| A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma | NCIC Clinical Trials Group | Phase 2 |
Clinical Trial Summary for AT9283
Top disease conditions for AT9283
Top clinical trial sponsors for AT9283
US Patents for AT9283
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
